Condition
Polycystic Kidney Disease, Adult
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results33% success
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05208866Phase 3TerminatedPrimary
Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
NCT04152837Phase 3TerminatedPrimary
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
NCT04407481CompletedPrimary
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Showing all 3 trials